Shree Ganesh Remedies Ltd. · BSE:SGRL
Shree Ganesh Remedies — Q1 FY27 Earnings Presentation
37 slides from Shree Ganesh Remedies's earnings presentation, Aug 13, 2026
Slide 1: Cover letter to BSE
August 13, 2026 To, Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400001 Script Code – 540737 Sub: Investor Presentation. With reference to the captioned subject, we enclose herewith the Investor Presentation with respect to Unaudited Financial Results of the Compan
Slide 2: Investor Presentation Q1FY27
Investor Presentation Q1FY27 Innovate. React. Transform.
Slide 3: Inside the Presentation
Inside the 19 20 Dahej Land Acquisition Setting the Stage for Large Scale Projects Driving Innovation Through Strategic R&D Investments Forward Presentation 21 22 State-of-the-Art R&D Infrastructure State-of-the-Art Pilot Infrastructure Looking Statement In so far as forecasts or 23 Accreditations t
Slide 4: Quarterly Highlights
Quarterly Highlights Management Commentary 04 P&L Summary 05 Balance Sheet Summary 06 Cash Flow Summary 07 04
Slide 5: Management Commentary
Q U AR TER LY HIG HL IG HTS Management Commentary Q1FY27 has been a challenging quarter for the Company. On the CRAMS front, our engagements in South-East Asia European demand has continued to remain subdued, with continue to progress in line with our expectations and a meaningful number of customer
Slide 6: P&L Summary
Q U AR TER LY HIG HL IG HTS P&L Summary YoY Change -42% -54% -68% Revenue EBITDA PAT YoY QoQ PARTICULARS ( ₹ IN C R OR E S ) Q1FY26 Q4FY26 Q1FY27 Change Change Revenue from Operations 24.67 33.20 14.36 -42% -57% Total Income 25.33 34.22 15.30 -40% -55% Operating Expenses 17.37 21.87 11.01 -37% -50%
Slide 7: Balance Sheet Summary
Q U AR TER LY HIG HL IG HTS Balance Sheet Summary PARTICULARS ( ₹ IN C R OR E S ) FY25 FY26 Shareholders' Funds 145.19 163.02 Non-Current Liabilities 30.60 23.03 Long Term Borrowings 29.48 21.25 Current Liabilities 16.18 21.69 Short Term Borrowings 8.76 9.42 Trade Payables 5.97 9.44 Total Equity and
Slide 8: Cash Flow Summary
Q U AR TER LY HIG HL IG HTS Cash Flow Summary PARTICULARS ( ₹ IN C R OR E S ) FY25 FY26 Cash from Operating Activities 30.66 23.75 Cash from Investing Activities -35.66 -9.89 Cash from Financing Activities -1.06 -11.70 Net Cash Flow -6.05 2.17 Cash at the Beginning of Year 15.78 9.90 Cash at the End
Slide 9: About the Business
About the Business Excellence in Complex Chemistry 09 Unparalleled Expertise in Advanced Chemical Synthesis 10 Unmatched Technology Prowess In Complex Chemical Reactions 12 Tailored Solutions Through Mastered Chemistry and Technology 13 Strategic Product Selection Criteria 14 Our Evolving Business M
Slide 10: Excellence in Complex Chemistry
ABO U T THE C O M P AN Y Excellence in Complex Chemistry Established Expertise Strategic Expansions Over 20 years of excellence in chemical Continuous investments in new manufacturing manufacturing, specialising in pharmaceutical blocks and R&D centers to enhance production intermediates and special
Slide 11: Unparalleled Expertise in Advanced Chemical Synthesis
ABO U T THE C O M P AN Y Unparalleled Core Strengths in Mastered Chemistries Expertise in Our company excels in the following core chemistries, with dedicated manufacturing blocks for each: Advanced 1. Halogenation Chemical • Chlorination: Using Thionyl Chloride, Sulphuryl Chloride, Oxalyl Chloride,
Slide 12: Unparalleled Expertise in Advanced Chemical Synthesis (Continued)
ABO U T THE C O M P AN Y Unparalleled Expertise in Advanced Chemical Synthesis (Continued) Additional Chemistries Other Reaction Capabilities While we currently do not have dedicated Heterocycle Synthesis 1 blocks for the following chemistries, we have Nitration 2 established a strong foothold and a
Slide 13: Unmatched Technology Prowess In Complex Chemical Reactions
ABO U T THE C O M P AN Y Unmatched Technology Prowess Key Technological Capabilities In Complex Liquid-Gas Reaction: Expertise in managing reactions involving both liquid and 1 Chemical gas phases, ensuring optimal reaction conditions and high yields. High-Pressure Reaction: Proficiency in conductin
Slide 14: Tailored Solutions Through Mastered Chemistry and Technology
ABO U T THE C O M P AN Y Tailored Solutions Through Mastered Chemistry and Technology Products by chemistry Industries Catered Chloro-Alkyl Amines HCl Salts Human and Veterinary Health Cyclopropane Derivatives Cyclobutane Derivatives Agrochemical Industry Carboxylic Acids & Acid Chlorides Aliphatic
Slide 15: Strategic Product Selection Criteria
ABO U T THE C O M P AN Y Strategic Product Chemistry Skillset The product must fall Technology Skillset Selection Margin Profile within the chemistry skills we have mastered. We must be capable of The product must meet our handling the complex internal benchmarks for processes involved, or we Criter
Slide 16: Our Evolving Business Model
ABO U T THE C O M P AN Y Our Evolving Business Model Inception Inception Pharmaceutical Intermediates Speciality and Fine Chemicals Since Company’s inception in 2004 Entered in 2010 Focus Focus Intermediates for Off-patent and generic drugs requiring control Moving towards patented molecules and cus
Slide 17: Collaborating With Industry Leaders
ABO U T THE C O M P AN Y Collaborating With Industry Leaders 16 Shree Gan es h Remedies L imited
Slide 18: Ankleshwar Site Expansion Fuelling Our Growth Strategy
ABO U T THE C O M P AN Y Ankleshwar Site Expansion Fuelling Our Growth Strategy Unit 1 Production Blocks • Currently 7 functional blocks • Block 8 added in FY24 • Block 7: To be commissioned in H1FY27 Block 8 • On going CAPEX for Plant 7 • Commissioning of all new Pilot Plant: implementing Automatio
Slide 19: Infrastructure at Ankleshwar Site
ABO U T THE C O M P AN Y Infrastructure at Ankleshwar Site 35 28 Glass Lined Reactors Stainless Steel Reactors 1000 to 25,000 Ltr 1000 to 15,000 Ltr *2 cryogenic (-30 Deg C) *1 cryogenic (-40 Deg C) 3 9 8 4 Autoclave Reactors Dryers Distillation Setup Warehouse 2000 Ltr 1000 to 2,500 Ltr Upto 70 Sta
Slide 20: Dahej Land Acquisition Setting the Stage for Large Scale Projects
ABO U T THE C O M P AN Y Dahej Land Acquisition Setting the Stage for Large Scale Projects Site Development • Initiated the construction of common infrastructure, utilities, and warehousing facilities Land Expansion Strategic Use Acquired 40,554 sq m land • Dahej site to host projects with large cor
Slide 21: Driving Innovation Through Strategic R&D Investments
ABO U T THE C O M P AN Y Driving Innovation R&D Lab Recognition Through Strategic Recognised by DSIR (Department of Scientific and Industrial Research), Central Government R&D Investments R&D and Process Team Composition 40 Total Team Members Global Expansion Exploring the setup of R&D facilities in
Slide 22: State-of-the-Art R&D Infrastructure
ABO U T THE C O M P AN Y State-of-the-Art R&D Infrastructure Key Facilities Advanced Analytical Labs Equipped with cutting-edge instruments for precise analysis Pilot Plants For scale-up studies and process optimisation Dedicated Synthesis Labs For novel compound development High-Performance Computi
Slide 23: State-of-the-Art Pilot Infrastructure
ABO U T THE C O M P AN Y State-of-the-Art Pilot Infrastructure As a critical enabler of our growth strategy, our Pilot Plant stands at the forefront of innovation, bridging the gap between research and commercial production. Vital Role in R&D and Scale-Up Expansion and Enhanced • Accelerates the tra
Slide 24: Accreditations that Speak to Our Comprehensive Standards
ABO U T THE C O M P AN Y Accreditations that Speak to Our Comprehensive Standards Indian GMP Certified ISO 9001:2015 Certified ISO 14001:2015 Certified ISO 45001:2018 Manufacturing Facility (Bureau Veritas) (Bureau Veritas) Certified (CCPL) DSIR Recognised Bronze Certified by ISO 14064:3 Certified H
Slide 25: Driving Innovation and Growth
ABO U T THE C O M P AN Y Driving Innovation and Growth Chandu Kothia Gunjan Kothia Parth Kothia Founding Promoter, Promoter, Promoter, Managing Director Head of Business Development & Innovation Whole Time Director, CFO Qualifications: Master of Science & Qualifications: BE in Chemical Engineering Q
Slide 26: Ensuring Health and Safety
ABO U T THE C O M P AN Y Ensuring Health and Safety Technical Personal Protection Organisational Health Measures Equipment Measures Check Closed charging and Working clothes with HAZOP compatible study Regular health check-ups discharging systems glasses and gloves on raw materials and finished prod
Slide 27: Protecting the Environment With Sustainable Practices
ABO U T THE C O M P AN Y Protecting the Environment With Sustainable Practices Conversion of In-house High- Biological Implemented a 2.5 flue gases to by- wastewater temperature waste water MW solar power products for treatment for incinerator for treatment park, expected to environmental recycling
Slide 28: Financial Highlights
Financial Highlights 5 Year Summary 28 Key Ratios 29 P&L Summary 30 Balance Sheet Summary 31 Cash Flow Summary 32 02
Slide 29: 5 Year Summary
F IN AN C IA L HIG HL IG HTS 5 Year Summary Revenue from Operations Profit After Tax EBITDA & EBITDA Margins EPS ( ₹ IN C R OR E S ) ( ₹ IN C R OR E S ) ( ₹ IN C R OR E S & IN % ) ( IN ₹ ) 36.1% 25 . 00 45 . 00 40 . 0% 33.2% 40 . 00 32.0% 35 . 0% 20 . 00 35 . 00 25.1% 25.7% 30 . 0% 35.02 109.29 30 .
Slide 30: Key Ratios
F IN AN C IA L HIG HL IG HTS Key Ratios ROE ROCE Equity & Debt to Equity Ratio Cash from Operating Activities ( IN % ) ( IN % ) ( ₹ IN C R OR E S & IN T IM E S ) ( ₹ IN C R OR E S ) 163.02 35 . 00 145.19 18 0. 0 0 0.38 122.11 30 . 00 16 0. 0 0 14 0. 0 0 25 . 00 23.75 87.20 12 0. 0 0 20 . 00 10 0. 0
Slide 31: P&L Summary
F IN AN C IA L HIG HL IG HTS P&L Summary CAGR 11% 18% 7% ( FY 21 - 25 ) Revenue EBITDA PAT PARTICULARS ( ₹ IN C R OR E S ) FY22 FY23 FY24 FY25 FY26 Revenue from Operations 71.29 91.36 125.90 108.60 109.29 Total Income 74.86 92.07 128.96 112.33 112.32 Operating Expenses 53.37 67.92 84.09 69.38 74.27
Slide 32: Balance Sheet Summary
F IN AN C IA L HIG HL IG HTS Balance Sheet Summary PARTICULARS ( ₹ IN C R OR E S ) FY22 FY23 FY24 FY25 FY26 Shareholders' Funds 61.57 87.20 122.11 145.19 163.02 Non-Current Liabilities 0.40 30.66 30.16 30.60 23.03 Long Term Borrowings 0.00 30.44 29.12 29.48 21.25 Current Liabilities 15.04 20.11 18.6
Slide 33: Cash Flow Summary
F IN AN C IA L HIG HL IG HTS Cash Flow Summary PARTICULARS ( ₹ IN C R OR E S ) FY22 FY23 FY24 FY25 FY26 Cash from Operating Activities 13.42 17.10 30.45 30.66 23.75 Cash from Investing Activities (11.91) (51.09) (33.09) (35.66) (9.89) Cash from Financing Activities (1.09) 38.66 9.85 (1.06) (11.70) N
Slide 34: Investment Merits
Investment Merits Investment Case 34 03
Slide 35: Investment Case
IN V ES TM E NT M E RI TS Investment Case Lean Balance Experienced Increasing Focus Available Land for Humongous Sheet: Management at on Complex Further Capacity Addressable The company the Helm: Molecules and Expansions: Opportunity Size: maintains a strong Led by a seasoned Niche Specialty With am
Slide 36: Market Statistics
Market Statistics Shareholding Pattern CURRENT MARKET PRICE ₹ 589.95 52 WEEK HIGH/LOW ₹ 759.00 / 381.10 MARKET CAPITALIZATION ₹ 757.20 Cr SHARES OUTSTANDING 1.28 Cr Promoter 72.83% BSE SCRIP CODE 540737 Public 27.17% Shareholding Data as on 30th June 2026 Market Price Data as on 12th August 2026 35
Slide 37: Contact Us
Contact Us Shree Ganesh Remedies Limited Headquarters: Plot No. 6002, 6003, 6011 & 6012, GIDC Estate, Ankleshwar, Gujarat India – 393002 Aditya Patel Abhishek Mehra Company Secretary Investor Relations Advisors Shree Ganesh Remedies Limited TIL Advisors Private Limited [email protected] a
Shree Ganesh Remedies — Q1 FY27 Earnings Presentation on 6ix